FDA Advisers Slam Lipocine ' s Testosterone Pill, Raising Doubts About ' Low T ' Drugs

Investors are fleeing from testosterone drugmaker Lipocine, but its FDA woes portend bigger challenges for companies developing new versions of the embattled hormone.

Source: Forbes.com Healthcare News - January 11, 2018 Category: Pharmaceuticals Authors: Arlene Weintraub, Contributor Tags: NASDAQ:LPCN Source Type: news